Results 251 to 260 of about 2,398,894 (298)

Antibody–Drug Conjugates for Immunology

Journal of Medicinal Chemistry, 2022
The application of antibody-drug conjugates (ADCs) to fields outside of oncology is increasing but is still relatively uncommon. A recent publication describes the conjugation of glucocorticoid receptor modulators to antibodies as a means of improving the separation between desired anti-inflammatory activity and unwanted systemic side effects.
openaire   +2 more sources

The Promise of Antibody–Drug Conjugates

New England Journal of Medicine, 2012
The promise of antibody–drug conjugates (ADCs) is the specific targeting of highly potent cytotoxic agents to malignant disease without adversely affecting normal tissues. We may be on the verge of fulfilling that promise. This moment has been more than 25 years in the making and has required technology development in every facet of the conception and ...
Beverly A, Teicher, James H, Doroshow
openaire   +2 more sources

Antibody–drug conjugates for cancer

The Lancet, 2019
Antibody-drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC is designed to selectively deliver the ultratoxic payload directly to the target cancer cells.
Cindy H, Chau, Patricia S, Steeg, William D, Figg   +2 more
openaire   +2 more sources

Antibody-Drug Conjugate Targets

Current Cancer Drug Targets, 2009
The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire   +2 more sources

Antibody–Drug Conjugate Payloads

2013
Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Jan, Anderl, Heinz, Faulstich, Torsten, Hechler, Michael, Kulke   +3 more
openaire   +2 more sources

Payloads of Antibody: Drug Conjugates

2015
The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire   +1 more source

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi, Cortes J, Roberto Carmagnani Pestana   +2 more
exaly  

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Annals of Oncology, 2021
Q Hong, A D Santin, V Picozzi
exaly  

Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer

International Journal of Molecular Sciences, 2022
Min-Duk Seo, Sang Gyu Park
exaly  

How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Drugs and Drug Candidates, 2023
Sharina Hamzah, Hui Yin Yow, Shi Xuan Low   +2 more
exaly